Antiviral therapy in a child with pediatric human immunodeficiency virus (HIV): case study of audiologic findings.
Over the past decade, much research has been conducted to determine the auditory consequences of human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS). This research, primarily using adult patients, has focused on the involvement of the central auditory nervous system (CANS). Measures of auditory evoked potentials, particularly the auditory brainstem response (ABR), can document changes in the CANS as the disease progresses and during treatment with antiviral therapies such as zidovudine (AZT) and didanosine (ddI). This case study presents the audiologic findings for a child with HIV infection. Evaluations were performed over a 2-year period prior to the initiation of antiviral therapy and following treatment. Audiologic measures included behavioral audiometry, tympanometry, otoacoustic emissions, and ABR latency/intensity functions and rate studies. Findings indicated a gradual shortening of all ABR component latencies following the initiation of antiviral therapy. In addition, a high-frequency hearing loss was detected during the final evaluation subsequent to 19 months of treatment with AZT and ddI.
Christensen
L A
LA
Department of Communication Disorders, Louisiana State University Medical Center, New Orleans 70112, USA.
Morehouse
C R
CR
Powell
T W
TW
Alchediak
T
T
Silio
M
M
D019380:Anti-HIV Agents / Q000009:adverse effects*; D002648:Child; D016057:Evoked Potentials, Auditory, Brain Stem; D005260:Female; D006679:HIV Seropositivity / Q000150:complications* / Q000188:drug therapy*; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced* / Q000175:diagnosis; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D010775:Photic Stimulation; D012720:Severity of Illness Index; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015215:Zidovudine